[{"id":"98570857-da2d-4f2b-8583-f91bb35461dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01381705","created_at":"2021-01-18T05:39:57.481Z","updated_at":"2024-07-02T16:37:22.066Z","phase":"","brief_title":"Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma","source_id_and_acronym":"NCT01381705","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" FCGR3A","pipe":" | ","alterations":" FCGR3A 158V","tags":["FCGR3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FCGR3A 158V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 259","initiation":"Initiation: 02/06/2012","start_date":" 02/06/2012","primary_txt":" Primary completion: 07/06/2012","primary_completion_date":" 07/06/2012","study_txt":" Completion: 07/06/2012","study_completion_date":" 07/06/2012","last_update_posted":"2017-05-17"}]